Medtide

Medtide Liabilities

The The Liabilities of Medtide (3880.HK) as of Nov 14, 2026 is 227.80 M CNY. In the previous year, The Liabilities was 853.88 M CNY — a change of -73.32% (lower).

Liabilities

227.80 MCNY

YoY

-73.32%

Last updated:

In 2025, Medtide's total liabilities amounted to 227.80 M CNY, a -73.32% difference from the 853.88 M CNY total liabilities in the previous year.

The Medtide Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
1.04 B CNY
Jan 1, 2022
1.04 B CNY
Jan 1, 2023
1.05 B CNY
Jan 1, 2024
853.88 M CNY
Jan 1, 2025
227.80 M CNY
The Medtide Liabilities history
YEARLiabilitiesYoY
227.80 MCNY-73.32%
853.88 MCNY-19.05%
1.05 BCNY+1.75%
1.04 BCNY+0.13%
1.04 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Medtide's Liabilities

Medtide's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Medtide's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Medtide's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Medtide's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Medtide’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Medtide stock

The Liabilities of Medtide is 227.80 M CNY in 2025.

The Liabilities of Medtide changed from 853.88 M CNY to 227.80 M CNY, representing a -73.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Medtide since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medtide

All Key Metrics — Medtide